- Home
- SEED vs BIVI Comparison
SEED vs BIVI Comparison
Compare SEED & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- BIVI
- Stock Information
- Founded
- SEED 1997
- BIVI 2013
- Country
- SEED China
- BIVI United States
- Employees
- SEED N/A
- BIVI N/A
- Industry
- SEED Farming/Seeds/Milling
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- BIVI Health Care
- Exchange
- SEED Nasdaq
- BIVI Nasdaq
- Market Cap
- SEED 18.0M
- BIVI 20.4M
- IPO Year
- SEED N/A
- BIVI N/A
- Fundamental
- Price
- SEED $2.58
- BIVI $3.06
- Analyst Decision
- SEED
- BIVI Strong Buy
- Analyst Count
- SEED 0
- BIVI 2
- Target Price
- SEED N/A
- BIVI $40.00
- AVG Volume (30 Days)
- SEED 59.3K
- BIVI 119.2K
- Earning Date
- SEED 09-27-2024
- BIVI 11-06-2024
- Dividend Yield
- SEED N/A
- BIVI N/A
- EPS Growth
- SEED N/A
- BIVI N/A
- EPS
- SEED 1.21
- BIVI N/A
- Revenue
- SEED $16,516,031.00
- BIVI N/A
- Revenue This Year
- SEED N/A
- BIVI N/A
- Revenue Next Year
- SEED N/A
- BIVI N/A
- P/E Ratio
- SEED $2.06
- BIVI N/A
- Revenue Growth
- SEED 64.93
- BIVI N/A
- 52 Week Low
- SEED $1.37
- BIVI $2.07
- 52 Week High
- SEED $6.38
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- SEED 51.55
- BIVI 53.15
- Support Level
- SEED $2.40
- BIVI $2.43
- Resistance Level
- SEED $2.73
- BIVI $3.34
- Average True Range (ATR)
- SEED 0.19
- BIVI 0.25
- MACD
- SEED 0.04
- BIVI 0.08
- Stochastic Oscillator
- SEED 60.00
- BIVI 77.47
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.